Shukra Pharmaceuticals touches roof on bagging contract from HSCC (India)
Shukra Pharmaceuticals is currently trading at upper limit of Rs. 26.22, up by 0.51 points or 1.98% from its previous closing of Rs. 25.71 on the BSE.
The scrip opened at Rs. 26.22 and has touched a high and low of Rs. 26.22 and Rs. 26.22 respectively. So far 262560 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 1 has touched a 52 week high of Rs. 27.15 on 05-Mar-2025 and a 52 week low of Rs. 5.75 on 21-Nov-2024.
Last one week high and low of the scrip stood at Rs. 26.22 and Rs. 23.33 respectively. The current market cap of the company is Rs. 1148.12 crore.
The promoters holding in the company stood at 50.96%, while Institutions and Non-Institutions held 0.11% and 48.93% respectively.
Shukra Pharmaceuticals has been awarded a prestigious contract by HSCC (India) (a Government of India Enterprise under the Ministry of Housing & Urban Affairs), acting on behalf of the Ministry of External Affairs, Government of India. The company has received a Letter of Award (LoA) on dated August 28, 2025 for the supply of Medicines and Diagnostic Kits to Afghanistan (Technical Mission of India, Kabul, Afghanistan).
The Letter of Award entails a total contract value of Rs 24.06 crore for the supply of essential Medicines and Diagnostic Kits, which includes packing, forwarding, insurance, and delivery at the consignee site in Afghanistan. This order further strengthens the company’s international presence and reaffirms the company’s capabilities to execute large-scale global healthcare supply projects, especially under Government of India backed initiatives.
Shukra Pharmaceuticals is an ambitious organisation with a deep-rooted focus on sustainability with its impressive range of solutions.
